The first and only fixed-dose combination of a beta blocker beta blocker (BB) and angiotensin II receptor blocker (ARB) for hypertension will be available in the US in the second half of the year. FDA approved nebivolol and valsartan (Byvalson, Allergan) 5 mg/80 mg tablets in early June.
A look at how burnout affects providers, their patients, and the centers that employ them.
Expanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.
ASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies
FDA recently approved daclizumab (Zinbryta, Biogen and AbbVie), a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS).
The ACA has done a lot of good, but key opinion leaders believe there’s still room for improvement.
Determining what to measure, and how best to measure it, can be surprisingly complex-and appropriate metrics can vary between cancer types and patient populations.
The hurdle for managed care organizations is not identifying individuals who may benefit from support, rather, it’s finding a way to tailor efforts to engage members in the solutions being offered.
The global oncology market was worth $107 billion in 2015, and global annual cancer drug costs surged by 11.5% from 2011 to 2015, according to a new report.
There’s no silver bullet for migraine treatments, but treatments are getting more precise as we learn more about the cause of migraines.
The CDC says that one out of three older adults falls each year, making falls the leading cause of injuries for adults 65 and older. Here’s how some hospitals and programs are addressing the problem.
Report offers some clues regarding healthcare spending disparities
FDA recently approved the first 4-strain, cell culture-derived, inactivated seasonal flu vaccine available in the United States. Flucelvax Quadrivalent influenza vaccine (Seqirus) helps protect against the 2 influenza A viruses and two B viruses recommended by the World Health Organization (WHO) and the FDA for the current influenza season.
In a major new entry in the diabetes market, FDA just approved linagliptin and metformin hydrochloride extended-release tablets (Jentadueto XR, Boehringer Ingelheim and Eli Lilly and Company) to treat type 2 diabetes.
A discussion with Thomas H. Lee, MD, chief medical officer, Press Ganey
Despite their proliferation, at-risk pharma contracts are still little more than value-based window dressing. Here are four critical components of contracts that can actually move the value meter in the right direction.
Industry experts are using their proprietary data/analysis to help structure contracts between pharmaceutical companies and plans.
Novo Nordisk’s new diabetes drug production facility in Clayton, N.C., will ensure production capacity for these drugs in the United States for the decade ahead.
A systemic review highlights studies that improved medication adherence and patient outcomes using strategies that could be effective if employed in real-world healthcare settings.
Drug shortages take a toll, especially on emergency department patients.
Preventing drug shortages requires a “swat team” mentality by all, including FDA, manufacturers, group purchasing organizations (GPOs), and health systems. Here’s what healthcare providers should do about the issue.
Preventing hospital readmissions must be top of mind for payers and providers, says Jill Duncan, RN, executive director at the Institute for Healthcare Improvement, where she leads the Joint Replacement Learning Community.
Successful healthcare systems share their strategies for reducing hospital readmissions.
Studies have found that getting diabetes under control early on has immediate benefits. Here’s how providers and patients can more proactively address the disease.
Specific benefits patients with diabetes have experienced due to the ACA, and how those benefits are impacting diabetes costs.
FDA recently granted accelerated approval for atezolizumab (Tecentriq, Genentech), the first drug for bladder cancer that utilizes the body’s immune system. The drug will be available by early June.
At the ASCO 2016 Annual Meeting, an expert from the Moffitt Cancer Center will discuss use of genetics to guide targeted-therapies and immunotherapies.
A value-based cancer care model focuses on better aligning providers with health plans and employers through an IPA.
